1
|
A Field Study Evaluating Humoral Immunity in Calves Vaccinated with Multivalent Bovine Respiratory Pathogen Vaccines. FOLIA VETERINARIA 2021. [DOI: 10.2478/fv-2021-0034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Bovine Respiratory Syncytial Virus (BRSV), Bovine Parainfluenza 3 (BPI3) and Mannheimia haemolytica (Mh) are major respiratory pathogens in the bovine respiratory disease complex. It is important to optimize passive and active immunity to these pathogens early in life to reduce clinical and subclinical productivity losses. The administration of inactivated, adjuvanted and multivalent vaccines, such as Bovilis® Bovipast RSP (Bovipast), and Bovalto® Respi 3 (Bovalto) to calves, may enhance cellular and humoral immunity against BRSV, BPI3 and Mh. A field trial evaluated the immune responses to these three agents in the first year of life in 12 Bovipast and 13 Bovalto vaccinated calves, and 5 negative control calves. Calves were vaccinated starting at 2 weeks of age and revaccinated 4 weeks later (primo vaccination). A booster vaccination was given at approximately 10 months of age. Serum samples were taken at time intervals up to 6 months after primo vaccination and up to 1 month after the booster vaccination. BRSV serum titres were evaluated using a serum neutralisation assay (SN), and BRSV, BPI3 and Mh titres were evaluated using a commercial enzyme linked immunosorbent assay (ELISA) test. Serum antibodies after primo and booster vaccinations in the individual calves were evaluated by calculating the areas under the curve (AUC) of the Log2 transformed BRSV SN titres and the optic density measures of the ELISA tests for BRSV, BPI3 and Mh. Multivariate general linear models were used to evaluate the influence of the vaccination on the AUC of the serum measures within 6 months after the primo vaccination. Similarly, models evaluated the AUC of the serum measures after the booster vaccination. The Bovipast vaccinated calves had significantly higher SN and ELISA titres AUC following the primo vaccination and booster vaccinations compared to the negative control calves and the Bovalto vaccinated calves. The Bovalto vaccinated calves did not have a significantly different BRSV SN and ELISA titres AUC response after the primo or booster vaccinations compared to the negative control calves. The serum antibody responses to BPI3 and Mh in the vaccinated calves were less pronounced than the Bovipast BRSV antibody response. Bovipast and Boval- to vaccinated calves mounted a significantly higher AUC ELISA OD for both BPI3 and Mh and the highest AUC was measured in the Bovipast vaccinated calves. This study indicated that early vaccinations of calves with multivalent adjuvanted inactivated BRD vaccines, such as Bovilis® Bovipast RSP can elicit a humoral response with a cellular-mediated memory effect as indicated by the booster vaccination.
Collapse
|
2
|
Lemon JL, McMenamy MJ. A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease. Vaccines (Basel) 2021; 9:vaccines9121403. [PMID: 34960149 PMCID: PMC8703677 DOI: 10.3390/vaccines9121403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2021] [Revised: 11/10/2021] [Accepted: 11/22/2021] [Indexed: 01/11/2023] Open
Abstract
Vaccination is widely regarded as a cornerstone in animal or herd health and infectious disease management. Nineteen vaccines against the major pathogens implicated in bovine respiratory disease are registered for use in the UK by the Veterinary Medicines Directorate (VMD). However, despite annual prophylactic vaccination, bovine respiratory disease is still conservatively estimated to cost the UK economy approximately £80 million per annum. This review examines the vaccine types available, discusses the surrounding literature and scientific rationale of the limitations and assesses the potential of novel vaccine technologies.
Collapse
Affiliation(s)
- Joanne L. Lemon
- Sustainable Agri-Food and Sciences Division, Agri-Food and Bioscience Institute, Newforge Lane, Belfast BT9 5PX, UK
- Correspondence:
| | - Michael J. McMenamy
- Veterinary Sciences Division, Agri-Food and Bioscience Institute, Stormont, Belfast BT4 3SD, UK;
| |
Collapse
|
3
|
Makoschey B, Berge AC. Review on bovine respiratory syncytial virus and bovine parainfluenza - usual suspects in bovine respiratory disease - a narrative review. BMC Vet Res 2021; 17:261. [PMID: 34332574 PMCID: PMC8325295 DOI: 10.1186/s12917-021-02935-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 06/10/2021] [Indexed: 12/26/2022] Open
Abstract
Bovine Respiratory Syncytial virus (BRSV) and Bovine Parainfluenza 3 virus (BPIV3) are closely related viruses involved in and both important pathogens within bovine respiratory disease (BRD), a major cause of morbidity with economic losses in cattle populations around the world. The two viruses share characteristics such as morphology and replication strategy with each other and with their counterparts in humans, HRSV and HPIV3. Therefore, BRSV and BPIV3 infections in cattle are considered useful animal models for HRSV and HPIV3 infections in humans. The interaction between the viruses and the different branches of the host’s immune system is rather complex. Neutralizing antibodies seem to be a correlate of protection against severe disease, and cell-mediated immunity is thought to be essential for virus clearance following acute infection. On the other hand, the host’s immune response considerably contributes to the tissue damage in the upper respiratory tract. BRSV and BPIV3 also have similar pathobiological and epidemiological features. Therefore, combination vaccines against both viruses are very common and a variety of traditional live attenuated and inactivated BRSV and BPIV3 vaccines are commercially available.
Collapse
Affiliation(s)
- Birgit Makoschey
- Intervet International BV/MSD-Animal Health, Wim de Körverstraat, 5831AN, Boxmeer, The Netherlands.
| | - Anna Catharina Berge
- Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, 9820, Merelbeke, Belgium
| |
Collapse
|
4
|
Klem TB, Sjurseth SK, Sviland S, Gjerset B, Myrmel M, Stokstad M. Bovine respiratory syncytial virus in experimentally exposed and rechallenged calves; viral shedding related to clinical signs and the potential for transmission. BMC Vet Res 2019; 15:156. [PMID: 31109324 PMCID: PMC6528318 DOI: 10.1186/s12917-019-1911-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 05/13/2019] [Indexed: 11/10/2022] Open
Abstract
Background Bovine respiratory syncytial virus (BRSV) is an important respiratory pathogen worldwide, detrimentally affecting the economy and animal welfare. To prevent and control BRSV infection, further knowledge on virus shedding and transmission potential in individual animals is required. This study aimed to detect viral RNA and infective virions during BRSV infection to evaluate duration of the transmission period and correlation with clinical signs of disease. The outcome of BRSV re-exposure on calves, their housing environment and effect of introduction of sentinel calves was also investigated. A live animal experiment including 10 calves was conducted over 61 days. Initially, two calves were inoculated with a non-passaged BRSV field isolate. Two days later, six naïve calves (EG: Exposed group) were introduced for commingling and four weeks later, another two naïve calves (SG: Sentinel group) were introduced. Seven weeks after commingling, EG animals were re-inoculated. Clinical examination was performed daily. Nasal swabs were collected regularly and analysed for viral RNA by RT-ddPCR, while virus isolation was performed in cell culture. BRSV serology was performed with ELISA. Results All the EG calves seroconverted and showed clinical signs of respiratory disease. Viral RNA was detected from days 1–27 after exposure, while the infective virus was isolated on day 6 and 13. On day 19, all animals were seropositive and virus could not be isolated. Total clinical score for respiratory signs corresponded well with the shedding of viral RNA. The SG animals, introduced 27 days after exposure, remained negative for BRSV RNA and stayed seronegative throughout the study. Inoculation of the EG calves seven weeks after primary infection did not lead to new shedding of viral RNA or clinical signs of disease. Conclusion Viral RNA was detected in nasal swabs from the calves up to four weeks after exposure. The detection and amount of viral RNA corresponded well with the degree of respiratory signs. The calves were shedding infective virions for a considerable shorter period, and naïve calves introduced after four weeks were not infected. Infected calves were protected from reinfection for at least seven weeks. This knowledge is useful to prevent spread of BRSV.
Collapse
Affiliation(s)
- Thea Blystad Klem
- Norwegian Veterinary Institute, P.O. Box 750 Sentrum, 0106, Oslo, Norway.
| | | | - Ståle Sviland
- Norwegian Veterinary Institute, P.O. Box 750 Sentrum, 0106, Oslo, Norway
| | - Britt Gjerset
- Norwegian Veterinary Institute, P.O. Box 750 Sentrum, 0106, Oslo, Norway
| | - Mette Myrmel
- Department of Food Safety and Infection Biology, Norwegian University of Life Sciences, P.O. Box 8146 Dep, 0033, Oslo, Norway
| | - Maria Stokstad
- Department of Production Animal Clinical Sciences, Norwegian University of Life Sciences, P.O. Box 8146 Dep, 0033, Oslo, Norway
| |
Collapse
|
5
|
|
6
|
Ellis JA. How efficacious are vaccines against bovine respiratory syncytial virus in cattle? Vet Microbiol 2017; 206:59-68. [DOI: 10.1016/j.vetmic.2016.11.030] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 11/22/2016] [Accepted: 11/30/2016] [Indexed: 10/20/2022]
|
7
|
Grissett GP, White BJ, Larson RL. Structured literature review of responses of cattle to viral and bacterial pathogens causing bovine respiratory disease complex. J Vet Intern Med 2015; 29:770-80. [PMID: 25929158 PMCID: PMC4895424 DOI: 10.1111/jvim.12597] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Revised: 01/14/2015] [Accepted: 03/23/2015] [Indexed: 12/01/2022] Open
Abstract
Bovine respiratory disease (BRD) is an economically important disease of cattle and continues to be an intensely studied topic. However, literature summarizing the time between pathogen exposure and clinical signs, shedding, and seroconversion is minimal. A structured literature review of the published literature was performed to determine cattle responses (time from pathogen exposure to clinical signs, shedding, and seroconversion) in challenge models using common BRD viral and bacterial pathogens. After review a descriptive analysis of published studies using common BRD pathogen challenge studies was performed. Inclusion criteria were single pathogen challenge studies with no treatment or vaccination evaluating outcomes of interest: clinical signs, shedding, and seroconversion. Pathogens of interest included: bovine viral diarrhea virus (BVDV), bovine herpesvirus type 1 (BHV‐1), parainfluenza‐3 virus, bovine respiratory syncytial virus, Mannheimia haemolytica, Mycoplasma bovis, Pastuerella multocida, and Histophilus somni. Thirty‐five studies and 64 trials were included for analysis. The median days to the resolution of clinical signs after BVDV challenge was 15 and shedding was not detected on day 12 postchallenge. Resolution of BHV‐1 shedding resolved on day 12 and clinical signs on day 12 postchallenge. Bovine respiratory syncytial virus ceased shedding on day 9 and median time to resolution of clinical signs was on day 12 postchallenge. M. haemolytica resolved clinical signs 8 days postchallenge. This literature review and descriptive analysis can serve as a resource to assist in designing challenge model studies and potentially aid in estimation of duration of clinical disease and shedding after natural pathogen exposure.
Collapse
Affiliation(s)
- G P Grissett
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - B J White
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - R L Larson
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| |
Collapse
|
8
|
Hägglund S, Hu K, Vargmar K, Poré L, Olofson AS, Blodörn K, Anderson J, Ahooghalandari P, Pringle J, Taylor G, Valarcher JF. Bovine respiratory syncytial virus ISCOMs-Immunity, protection and safety in young conventional calves. Vaccine 2011; 29:8719-30. [PMID: 21864616 PMCID: PMC7115641 DOI: 10.1016/j.vaccine.2011.07.146] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2011] [Revised: 07/21/2011] [Accepted: 07/29/2011] [Indexed: 01/18/2023]
Abstract
Bovine respiratory syncytial virus (BRSV) is a major cause of bronchiolitis and pneumonia in cattle and causes yearly outbreaks with high morbidity in Europe. Commercial vaccines against this virus needs improvement of efficacy, especially in calves with BRSV-specific maternally derived antibodies (MDA). We previously reported that an experimental BRSV-ISCOM vaccine, but not a commercial vaccine, induced strong clinical and virological protection in calves with MDA, immunized at 7–15 weeks of age. The aim of the present study was to characterize the immune responses, as well as to investigate the efficacy and safety in younger animals, representing the target population for vaccination. Four groups of five 3–8 week old calves with variable levels of BRSV-specific MDA were immunized s.c. twice at a 3 weeks interval with (i) BRSV immunostimulating complexes (BRSV-ISCOMs), (ii) BRSV-protein, (iii) adjuvant, or (iv) PBS. All calves were challenged with virulent BRSV by aerosol 2 weeks later and euthanized on day 6 after infection. The cellular and humoral responses were monitored as well as the clinical signs, the viral excretion and the pathology following challenge. Despite presence of MDA at the time of the immunization, only a minimum of clinical signs were observed in the BRSV-ISCOM group after challenge. In contrast, in all control groups, clinical signs of disease were observed in most of the animals (respiratory rates up to 76 min−1 and rectal temperatures up to 41 °C). The clinical protection was associated to a highly significant reduction of virus replication in the upper and lower respiratory tract of calves, rapid systemic and local antibody responses and T helper cell responses dominated by IFNγ production. Animals that did not shed virus detectable by PCR or cell culture following challenge possessed particularly high levels of pulmonary IgA. The protective immunological responses to BRSV proteins and the ability to overcome the inhibiting effect of MDA were dependent on ISCOM borne antigen presentation.
Collapse
Affiliation(s)
- Sara Hägglund
- Swedish University of Agricultural Sciences, Department of Clinical Sciences, Uppsala, Sweden.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ellis JA, Gow SP, Goji N. Response to experimentally induced infection with bovine respiratory syncytial virus following intranasal vaccination of seropositive and seronegative calves. J Am Vet Med Assoc 2010; 236:991-9. [PMID: 20433400 DOI: 10.2460/javma.236.9.991] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To determine whether a combination modified-live bovine respiratory syncytial virus (BRSV) vaccine can stimulate protective immunity in young BRSV-seropositive calves following intranasal (IN) administration. DESIGN Controlled challenge study. ANIMALS 66 Holstein bull calves, 3 to 8 days old. PROCEDURES In experiment 1, BRSV-seropositive and -seronegative calves were vaccinated IN with a commercially available combination modified-live virus vaccine formulated for SC administration; calves underwent BRSV challenge 4.5 months later. In experiment 2, BRSV-seronegative calves were vaccinated IN or SC (to examine the effect of route of administration) with the same combination vaccine that instead had a 1/100 dose of BRSV (to examine the effect of dose); calves underwent BRSV challenge 21 days later. RESULTS In experiment 1, BRSV challenge resulted in severe respiratory tract disease with low arterial partial pressures of oxygen and lung lesions in most calves from all groups. Maximum change in rectal temperature was significantly greater in seropositive IN vaccinated calves, compared with seronegative IN vaccinated and seropositive control calves. Number of days of BRSV shedding was significantly lower in seronegative IN vaccinated calves than in seropositive IN vaccinated and seropositive control calves. In experiment 2, maximum change in rectal temperature was significantly greater in seronegative control calves, compared with seronegative IN and SC vaccinated calves. Shedding of BRSV was significantly reduced in seronegative IN and SC vaccinated calves, compared with control calves; also, lung lesions were reduced in seronegative IN and SC vaccinated calves. CONCLUSIONS AND CLINICAL RELEVANCE Maternal antibodies may inhibit priming of protective responses by IN delivered BRSV vaccines.
Collapse
Affiliation(s)
- John A Ellis
- Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada.
| | | | | |
Collapse
|
10
|
van der Sluijs MTW, Kuhn EM, Makoschey B. A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody. BMC Vet Res 2010; 6:2. [PMID: 20064236 PMCID: PMC2824702 DOI: 10.1186/1746-6148-6-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2009] [Accepted: 01/11/2010] [Indexed: 11/30/2022] Open
Abstract
Background The efficacy of a single dose of an inactivated bovine respiratory syncytial virus (BRSV) - Parainfluenaza type 3 (PI3) - Mannheimia haemolytica (Mh) combination vaccine, in calves positive for maternal antibodies, was established in a BRSV infection study. Results As expected the single vaccination did not have any effect on the decline of BRSV-specific neutralising or ELISA antibody. The cellular immune system was however primed by the vaccination. In the vaccinated group virus excretion with nasal discharge was reduced, less virus could be re-isolated from lung tissues and the lungs were less affected. Conclusions These results indicate that a single vaccination with an inactivated BRSV vaccine was able to break through the maternal immunity and induce partial protection in very young calves. It can be speculated that the level and duration of protection will improve after the second dose of vaccine is administered. A two-dose basic vaccination schedule is recommended under field conditions.
Collapse
Affiliation(s)
- Mirjam T W van der Sluijs
- Global Ruminant Business Unit, Intervet International bv, Wim de Körverstraat 35, NL-5831 AN Boxmeer, the Netherlands
| | | | | |
Collapse
|
11
|
Assié S, Seegers H, Makoschey B, Désiré-Bousquié L, Bareille N. Exposure to pathogens and incidence of respiratory disease in young bulls on their arrival at fattening operations in France. Vet Rec 2009; 165:195-9. [PMID: 19684344 DOI: 10.1136/vr.165.7.195] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The incidence of clinical respiratory disease in 698 young beef bulls kept in 68 pens, and their exposure to respiratory pathogens after their arrival at 51 fattening operations in western France were assessed. Antibodies against bovine respiratory syncytial virus (BRSV), bovine herpesvirus type 1 (BHV-1), Mannheimia haemolytica and Mycoplasma bovis were measured by ELISA. The incidence risk of respiratory disease was 18.5 per cent during the first six weeks. Cases occurred in 37 of the 68 pens, and in these pens 30.9 per cent of the bulls were affected. Their exposure to BHV-1 was very limited. When they arrived a high proportion of the bulls were seropositive to M haemolytica and a high proportion seroconverted to BRSV, M haemolytica and M bovis within the first six weeks. The risk of incidence of respiratory disease was lower in the pens in which the bulls had been vaccinated against M haemolytica. Higher proportions of the bulls were affected in pens in which small proportions of the bulls were seropositive to M haemolytica or BRSV on arrival, and in pens in which high proportions of the bulls were exposed to M haemolytica or BRSV during the first six weeks.
Collapse
Affiliation(s)
- S Assié
- UMR 1300 Unit of Bio-aggression, Epidemiology and Risk Analysis, Veterinary School, INRA, BP 40706, F-44307, Nantes, Cedex 03, France.
| | | | | | | | | |
Collapse
|
12
|
Platt R, Widel PW, Kesl LD, Roth JA. Comparison of humoral and cellular immune responses to a pentavalent modified live virus vaccine in three age groups of calves with maternal antibodies, before and after BVDV type 2 challenge. Vaccine 2009; 27:4508-19. [PMID: 19446589 DOI: 10.1016/j.vaccine.2009.05.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Revised: 05/06/2009] [Accepted: 05/07/2009] [Indexed: 10/20/2022]
Abstract
The aim of this study was to evaluate the ability of a pentavalent (BVDV types 1 and 2, BHV-1, BRSV, and PI-3) modified live virus (MLV) vaccine given to 1-2-, 4-5-, and 7-8-week-old calves with maternal antibodies to induce humoral and cellular immune responses and protect calves from virulent BVDV type 2. Eight calves in each age group were vaccinated and four served as controls. All calves were challenged intranasally with BVDV type 2, 12 weeks after vaccination. SVN titers to all five viruses declined in all groups after vaccination (except 4-5-week-old calves to BVDV type 1). After challenge, the SVN titers for both types of BVDV showed anamnestic responses in calves vaccinated at 4-5 and 7-8 weeks, but not at 1-2 weeks of age. In all groups, T cell subsets responded specifically to BVDV types 1 and 2 but not to BHV-1, BRSV, or PI-3 after vaccination by increasing their expression of activation markers (CD25, IFN-gamma and IL-4). All vaccinated calves were significantly protected from BVDV type 2 challenge.
Collapse
Affiliation(s)
- Ratree Platt
- Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, United States
| | | | | | | |
Collapse
|
13
|
Makoschey B, Muñoz Bielsa J, Oliviero L, Roy O, Pillet F, Dufe D, Valla G, Cavirani S. Field efficacy of combination vaccines against bovine respiratory pathogens in calves. Acta Vet Hung 2008; 56:485-93. [PMID: 19149103 DOI: 10.1556/avet.56.2008.4.6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The efficacy of an inactivated bovine respiratory syncytial virus (BRSV)--bovine parainfluenza type 3 (PI3)--Mannheimia haemolytica (Mh) combination vaccine was examined in two field studies. Calves were vaccinated (i) with the inactivated vaccine, (ii) a modified live/killed viral combination vaccine, or (iii) left unvaccinated. The efficacy of the vaccines was judged by the (i) number of treated animals, (ii) number of individual antibiotic treatments per calf and (iii) mortality rates. After vaccination with the inactivated vaccine, the number of calves requiring antibiotic treatment was significantly lower than in the unvaccinated group (odds ratios: 0.26 first study and 0.53 second study), but differences between vaccination with live/killed combination vaccines and controls were not significant (odds ratios: 0.56 and 0.90, respectively). In both studies, a number of unvaccinated controls died due to respiratory disease (4.6% first and 6.7% second study). By contrast, none of the animals vaccinated with the inactivated vaccine died in the first study and only 3.3% in the second study. The mortality rates for the groups vaccinated with the live vaccine (1.3% and 7.8%) were similar to the unvaccinated controls. In summary, these data demonstrate the efficacy of the inactivated vaccine under field conditions.
Collapse
Affiliation(s)
- Birgit Makoschey
- 1 Intervet Schering-Plough Animal Health Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
| | - Juan Muñoz Bielsa
- 1 Intervet Schering-Plough Animal Health Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
| | | | | | | | - Divine Dufe
- 1 Intervet Schering-Plough Animal Health Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
| | - Giorgio Valla
- 4 Intervet Italy S.r.l. Peschiera Borromeo (MI) Italy
| | | |
Collapse
|
14
|
Abstract
In this article we cover the immunologic response as it develops, the components of passive immunity, and the immune response of young calves. We discuss interference from maternal immunity in the development of specific immunity and vaccine strategies for developing protection against pathogens in calves.
Collapse
|
15
|
Meyer G, Deplanche M, Schelcher F. Human and bovine respiratory syncytial virus vaccine research and development. Comp Immunol Microbiol Infect Dis 2007; 31:191-225. [PMID: 17720245 DOI: 10.1016/j.cimid.2007.07.008] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/12/2007] [Indexed: 11/23/2022]
Abstract
Human (HRSV) and bovine (BRSV) respiratory syncytial viruses (RSV) are two closely related viruses, which are the most important causative agents of respiratory tract infections of young children and calves, respectively. BRSV vaccines have been available for nearly 2 decades. They probably have reduced the prevalence of RSV infection but their efficacy needs improvement. In contrast, despite decades of research, there is no currently licensed vaccine for the prevention of HRSV disease. Development of a HRSV vaccine for infants has been hindered by the lack of a relevant animal model that develops disease, the need to immunize immunologically immature young infants, the difficulty for live vaccines to find the right balance between attenuation and immunogenicity, and the risk of vaccine-associated disease. During the past 15 years, intensive research into a HRSV vaccine has yielded vaccine candidates, which have been evaluated in animal models and, for some of them, in clinical trials in humans. Recent formulations have focused on subunit vaccines with specific CD4+ Th-1 immune response-activating adjuvants and on genetically engineered live attenuated vaccines. It is likely that different HRSV vaccines and/or combinations of vaccines used sequentially will be needed for the various populations at risk. This review discusses the recent advances in RSV vaccine development.
Collapse
Affiliation(s)
- Gilles Meyer
- INRA-ENVT, UMR1225 IHAP, Interactions Hôtes-Virus et Vaccinologie, Ecole Nationale Vétérinaire, 23 Chemin des Capelles, BP 87614, 31076 Toulouse Cedex, France.
| | | | | |
Collapse
|
16
|
Arcangioli MA, Duet A, Meyer G, Dernburg A, Bézille P, Poumarat F, Le Grand D. The role of Mycoplasma bovis in bovine respiratory disease outbreaks in veal calf feedlots. Vet J 2007; 177:89-93. [PMID: 17493850 DOI: 10.1016/j.tvjl.2007.03.008] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2006] [Revised: 02/21/2007] [Accepted: 03/16/2007] [Indexed: 11/18/2022]
Abstract
To assess the prevalence and relative importance of Mycoplasma bovis among the pathological agents implicated in bovine respiratory disease (BRD), we surveyed 135 veal calves from nine feedlots in eastern France during naturally occurring outbreaks of respiratory disease. Occurrence of respiratory pathogens, M. bovis, bovine viral diarrhoea (BVD) virus, bovine respiratory syncytial (BRS) virus and parainfluenza-3 (PI3) virus was investigated by seroconversion and isolation of bacteria and viruses from broncho-alveolar fluids. M. bovis and pathogenic respiratory bacteria were isolated in eight of the nine feedlots, and from 106 and 32, respectively, of the 135 tested animals. Seroconversion to PI3 virus occurred in four lots. BVD and BRS viruses were detected in eight and one lot, respectively. M. bovis was the most frequently isolated aetiologic agent in these BRD outbreaks, spreading early and widely throughout the affected units (60-100% rate of isolation and seroconversion). These results stress the importance of M. bovis in the BRD complex.
Collapse
Affiliation(s)
- Marie-Anne Arcangioli
- Unité Mixte de Recherche Mycoplasmoses des Ruminants, Ecole Vétérinaire de Lyon, 1 avenue Bourgelat, 69280 Marcy l'Etoile, France.
| | | | | | | | | | | | | |
Collapse
|
17
|
Boxus M, Tignon M, Roels S, Toussaint JF, Walravens K, Benoit MA, Coppe P, Letesson JJ, Letellier C, Kerkhofs P. DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge. J Virol 2007; 81:6879-89. [PMID: 17459933 PMCID: PMC1933320 DOI: 10.1128/jvi.00502-07] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Respiratory syncytial viruses (RSV) are one of the most important respiratory pathogens of humans and cattle, and there is currently no safe and effective vaccine prophylaxis. In this study, we designed two codon-optimized plasmids encoding the bovine RSV fusion (F) and nucleocapsid (N) proteins and assessed their immunogenicity in young calves. Two administrations of both plasmids elicited low antibody levels but primed a strong cell-mediated immunity characterized by lymphoproliferative response and gamma interferon production in vitro and in vivo. Interestingly, this strong cellular response drastically reduced viral replication, clinical signs, and pulmonary lesions after a highly virulent challenge. Moreover, calves that were further vaccinated with a killed-virus vaccine developed high levels of neutralizing antibody and were fully protected following challenge. These results indicate that DNA vaccination could be a promising alternative to the classical vaccines against RSV in cattle and could therefore open perspectives for vaccinating young infants.
Collapse
Affiliation(s)
- Mathieu Boxus
- Biologie Cellulaire et Moléculaire, Faculté des Sciences Agronomiques, 5030 Gembloux, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Vangeel I, Antonis AFG, Fluess M, Riegler L, Peters AR, Harmeyer SS. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV. Vet J 2006; 174:627-35. [PMID: 17169592 DOI: 10.1016/j.tvjl.2006.10.013] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2006] [Revised: 07/21/2006] [Accepted: 10/20/2006] [Indexed: 11/21/2022]
Abstract
Two experimental bovine respiratory syncytial virus (BRSV) challenge studies were undertaken to evaluate the efficacy of a single intranasal dose of a bivalent modified live vaccine containing BRSV in 3-week-old calves. In the first study, vaccine efficacy was evaluated in colostrum deprived (maternal antibody negative) calves 5, 10 and 21 days after vaccination. Nasal shedding of BRSV was significantly reduced in vaccinated calves challenged 10 or 21 days after vaccination. Virus excretion titres were also reduced in vaccinates challenged 5 days after vaccination but reduction in duration of shedding and total amount of virus shed were not statistically significant. Clinical disease after challenge in this study was mild. In the second study, vaccine efficacy was assessed in calves with maternal antibodies against BRSV by challenge 66 days post-vaccination. Vaccination significantly reduced nasal shedding after challenge and the severity of clinical disease was also reduced.
Collapse
Affiliation(s)
- Ilse Vangeel
- Pfizer Animal Health, Veterinary Medicine Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.
| | | | | | | | | | | |
Collapse
|